Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Ornella Di Bella"'
Autor:
Valentina Laquintana, Carla Mottini, Francesco Marchesi, Benedetta Marcozzi, Irene Terrenato, Eleonora Sperandio, Luisa de Latouliere, Francesca Carrieri, Fulvia Pimpinelli, Martina Pontone, Raul Pellini, Flaminia Campo, Laura Conti, Celeste Accetta, Chiara Mandoj, Fabrizio Petrone, Ornella Di Bella, Branka Vujovic, Aldo Morrone, Mirco Compagnone, Eugenia Principato, Eleonora Pinto, Elena Papa, Paolo Falcucci, Antonia La Malfa, Matteo Pallocca, Federico De Marco, Giulia Piaggio, Gennaro Ciliberto, Andrea Mengarelli, Simona di Martino
Publikováno v:
Frontiers in Immunology, Vol 14 (2024)
BackgroundFew data are available about the durability of the response, the induction of neutralizing antibodies, and the cellular response upon the third dose of the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in hemato-
Externí odkaz:
https://doaj.org/article/c4563b247fe145c784db4069a4f5b112
Autor:
Vincenza Frisardi, Oronzo Brunetti, Vincenza Abbinante, Marco Ardigò, Giuseppina Caolo, Annunziata Di Turi, Alessandra Torsello, Christian Napoli, Rita Mancini, Valeria Belleudi, Antonio Addis, Ornella Di Bella, Gennaro Ciliberto, Antonino Neri, Romina Corsini, Patrizia Ruggieri, Chiara Pollorsi, Nicola Silvestris
Publikováno v:
Frontiers in Public Health, Vol 11 (2023)
ObjectiveTo evaluate the impact of the COVID-19 pandemic on first and follow-up visits for cancer outpatients.MethodsThis is a multicenter retrospective observational study involving three Comprehensive Cancer Care Centers (CCCCs): IFO, including IRE
Externí odkaz:
https://doaj.org/article/92e3f7ad439445be92cd0bdf65cff499
Autor:
Dario Graceffa, Francesca Sperati, Claudio Bonifati, Gabriele Spoletini, Viviana Lora, Fulvia Pimpinelli, Martina Pontone, Raul Pellini, Ornella Di Bella, Aldo Morrone, Antonio Cristaudo
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
IntroductionPsoriasis has not been directly linked to a poor prognosis for COVID-19, yet immunomodulatory agents used for its management may lead to increased vulnerability to the dangerous complications of SARS-CoV-2 infection, as well as impair the
Externí odkaz:
https://doaj.org/article/2ee5bdf830b8489fba8979f50fd41810
Autor:
Fulvia Pimpinelli, Francesco Marchesi, Giulia Piaggio, Diana Giannarelli, Elena Papa, Paolo Falcucci, Antonio Spadea, Martina Pontone, Simona Di Martino, Valentina Laquintana, Antonia La Malfa, Enea Gino Di Domenico, Ornella Di Bella, Gianluca Falzone, Fabrizio Ensoli, Branka Vujovic, Aldo Morrone, Gennaro Ciliberto, Andrea Mengarelli
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-4 (2021)
Abstract In a population of 42 Philadelphia negative myeloproliferative neoplasm patients, all on systemic active treatment, the likelihood of responding to anti-SARS-CoV-2 BNT162b2 vaccine at 2 weeks after the second dose was significantly lower in
Externí odkaz:
https://doaj.org/article/163cb00c03834c19a2a1cc8a6df44d82
Autor:
Fulvia Pimpinelli, Francesco Marchesi, Giulia Piaggio, Diana Giannarelli, Elena Papa, Paolo Falcucci, Martina Pontone, Simona Di Martino, Valentina Laquintana, Antonia La Malfa, Enea Gino Di Domenico, Ornella Di Bella, Gianluca Falzone, Fabrizio Ensoli, Branka Vujovic, Aldo Morrone, Gennaro Ciliberto, Andrea Mengarelli
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-12 (2021)
Abstract Background Safety and immunogenicity of BNT162b2 mRNA vaccine are unknown in hematological patients; both were evaluated prospectively in 42 patients with multiple myeloma (MM) and 50 with myeloproliferative malignancies (MPM) (20 chronic my
Externí odkaz:
https://doaj.org/article/cfc7ce684fee41a18bf2ab074321ff0e
Autor:
Raul Pellini, Aldo Venuti, Fulvia Pimpinelli, Elva Abril, Giovanni Blandino, Flaminia Campo, Laura Conti, Armando De Virgilio, Federico De Marco, Enea Gino Di Domenico, Ornella Di Bella, Simona Di Martino, Fabrizio Ensoli, Diana Giannarelli, Chiara Mandoj, Valentina Manciocco, Paolo Marchesi, Francesco Mazzola, Silvia Moretto, Gerardo Petruzzi, Fabrizio Petrone, Barbara Pichi, Martina Pontone, Jacopo Zocchi, Antonello Vidiri, Branka Vujovic, Giulia Piaggio, Aldo Morrone, Gennaro Ciliberto
Publikováno v:
Vaccines, Vol 9, Iss 7, p 685 (2021)
Background: The first goal of the study was to analyse the antibody titre 21 days after the first dose of the BNT162b2 vaccine in a group of 252 healthcare workers (HCW). The second goal was to analyse how the antibody titre changes in correlation wi
Externí odkaz:
https://doaj.org/article/c4b16b645f8d4877bfc1a2bc05f44004
Autor:
Giuseppe La Torre, Valeria D’Egidio, Cristina Sestili, Rosario Andrea Cocchiara, Sara Cianfanelli, Ornella Di Bella, Lorenza Lia, Barbara Dorelli, Vittoria Cammalleri, Insa Backhaus, Federica Pagano, Chiara Anguissola, Amelia Vitiello, Rita Carsetti, Alice Mannocci, Giochiamo Collaborative Group
Publikováno v:
Vaccines, Vol 8, Iss 2, p 280 (2020)
Background: Vaccines simulate the first contact with infectious agents and evoke the immunological response without causing the disease and its complications. High rates of immunization among the population guarantee the interruption of the transmiss
Externí odkaz:
https://doaj.org/article/4ca354e66be24321a569b8e00c53cfe0
Autor:
Francesco Cognetti, Aldo Morrone, Diana Giannarelli, Domenico Bracco, Raul Pellini, Antonia Marina La Malfa, Laura Conti, Ornella Di Bella, Paolo Carlini, Gianluigi Ferretti, Virginia Ferraresi, Chiara Mandoj, Fabrizio Petrone, Maria Di Santo, Emanuela Taraborelli, Flaminia Campo, Alessandro Monti, Martina Pontone, Ludovica Gariazzo, Maria Teresa Maccallini, Vittoria Barberi, Davide Renna, Fulvia Pimpinelli, Vincenzo Di Noia
Supplementary Materials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4605351d15b0447794fa9dfdfd79b281
https://doi.org/10.1158/1078-0432.22482476
https://doi.org/10.1158/1078-0432.22482476
Autor:
Francesco Cognetti, Aldo Morrone, Diana Giannarelli, Domenico Bracco, Raul Pellini, Antonia Marina La Malfa, Laura Conti, Ornella Di Bella, Paolo Carlini, Gianluigi Ferretti, Virginia Ferraresi, Chiara Mandoj, Fabrizio Petrone, Maria Di Santo, Emanuela Taraborelli, Flaminia Campo, Alessandro Monti, Martina Pontone, Ludovica Gariazzo, Maria Teresa Maccallini, Vittoria Barberi, Davide Renna, Fulvia Pimpinelli, Vincenzo Di Noia
Purpose:We assessed the immunogenicity and safety of the BNT162b2 vaccine in a large cohort of patients with cancer (CP).Experimental Design:From March 1, 2021 to March 20, 2021, this prospective cohort study included 816 CP afferent to our instituti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::042dd2f6eae2cbd39f65236063b29e7b
https://doi.org/10.1158/1078-0432.c.6530936.v1
https://doi.org/10.1158/1078-0432.c.6530936.v1
Autor:
Simona di Martino, Gianluca Falzone, Francesco Marchesi, Gennaro Ciliberto, Enea Gino Di Domenico, Valentina Laquintana, Antonia La Malfa, Ornella Di Bella, Elena Papa, Martina Pontone, Branka Vujovic, Paolo Falcucci, Diana Giannarelli, Fulvia Pimpinelli, Fabrizio Ensoli, Aldo Morrone, Andrea Mengarelli, Giulia Piaggio
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-12 (2021)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
Background Safety and immunogenicity of BNT162b2 mRNA vaccine are unknown in hematological patients; both were evaluated prospectively in 42 patients with multiple myeloma (MM) and 50 with myeloproliferative malignancies (MPM) (20 chronic myeloid leu